Impact of genotype and mutation type on health-related quality of life in patients with hereditary hemorrhagic telangiectasia

Acta Oto-Laryngologica

Volumn 129, Issue 8, 2009, Pages 862-866

  Pfister, Markus ^a   Zalaman, Ilse M ^a   Blumenstock, Gunnar ^b   Mauz, Paul Stefan ^a   Baumann, Ingo ^c  

^a Department of Otolaryngology Head and Neck Surgery ^*  (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

ALK 1; AVM; ENG; Epistaxis; Genetics; HHT; Morbus Osler Rendu; Nose bleeding; QOL; Quality of life; SF 36

Indexed keywords

EDETIC ACID; ENDOGLIN;

ACTIVIN RECEPTOR LIKE KINASE 1 GENE; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; EFFECT SIZE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATOR GENE; NONSENSE MUTATION; PRIORITY JOURNAL; QUALITY OF LIFE; RENDU OSLER WEBER DISEASE; SHORT FORM 36;

ACTIVIN RECEPTORS, TYPE II; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CODON, NONSENSE; FEMALE; GENOTYPE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; QUALITY OF LIFE; RECEPTORS, CELL SURFACE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; YOUNG ADULT;

EID: 70350350080     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480802468138     Document Type: Article

References (20)

1. Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: A clinical analysis. J Med Genet 1992;/29:/ 527-530
2. Vase P, Grove O. Gastrointestinal lesions in hereditary hemorrhagic telangiectasia. Gastroenterology 1986;/91:/ 1079-1083
3. Letteboer TG, Zewald RA, Kamping EJ, de Haas G, Mager JJ, Snijder RJ, et al. Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutation in Dutch patients. Hum Genet 2005;/116:/8-16.
4. Geisthoff UW, Heckmann K, D'Amelio R, Grünewald S, Knöbber D, Falkai P, et al. Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 2007;136:726-33; discussion 734-735
5. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;/91:/66-7.
6. Pasculli G, Resta F, Guastamacchia E, Di Gennaro L, Suppressa P, Sabbà C. Health-related quality of life in a rare disease: hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease. Qual Life Res 2004;/13:/ 1715-1723
7. Bayrak-Toydemir P, McDonald J, Arkusu N, Toydemir RM, Calderon F, Tuncali T, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet 2006;/140:/2155-62.
8. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000;284:3043-3045
9. Schulte C, Geisthoff U, Lux A, Kupka S, Zenner HP, Blin N, et al. High frequency of ENG and ALK1/ACVRL1 mutations in German HHT patients. Hum Mutat 2005;/25:/ 595-601.
10. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;/8:/345- 51.
11. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;/13:/189-95.
12. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. BMJ 2002;/324:/1417.
13. Ware JE. The SF-36 Health Survey Update. Spine 2000;/25:/ 3130-3219
14. Bullinger M, Kirchberger I. SF-36 Fragebogen zum Gesundheitszustand. Handanweisung. Bern: Hogrefe Verlag fü r Psychologie Göttingen; 1998.
15. Kurth BM, Ellert U. The SF-36 questionnaire and its usefulness in population studies: results of the German Health Interview and Examination Survey 1998. Soz Prä- ventivmed 2002;/47:/266-77.
16. Cohen J. Quantitative methods in psychology: A power primer. Psychol Bull 1992;/112:/155-9.
17. Berg JN, Guttmacher AE, Marchuk DA, Porteous ME. Clinical heterogeneity in hereditary haemorrhagic telangiectasia: Are pulmonary arteriovenous malformations more common in families linked to endoglin? J Med Genet 1996;/33:/256-7.
18. Marchuk DA. Genetic abnormalities in hereditary hemorrhagic telangiectasia. Curr Opin Hematol 1998;/5:/332-8.
19. McDonald JE, Miller FJ, Hallam SE, Nelson L, Marchuk DA, Ward KJ. Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 2000;/93:/320-7.
20. Karapantzos I, Tsimpiris N, Goulis DG, Van Hoecke H, Van Cauwenberge P, Danielides V. Management of epistaxis in hereditary hemorrhagic teleangiectasia by Nd:YAG laser and quality of life assessment using HR-QOL questionnaire. Eur Arch Otorhinolaryngol 2005;/262:/830-3.